SCHEMBL7028093

SCHEMBL7028093

CCS(=O)(=O)NC(C(=O)NCCc1cc(Br)c(OCC#Cc2ccc(Br)cc2)c(OC)c1)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 1/20 0.36
GRK2 P25098 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
RAB9A P51151 1/20 0.34
MAPT P10636 2/20 0.34
MMP1 P03956 2/20 0.34
MMP9 P14780 1/20 0.34
MMP13 P45452 1/20 0.34
ADAM17 P78536 1/20 0.34
ALDH1A1 P00352 3/20 0.34
MAPK1 P28482 1/20 0.34
PTGER1 P34995 1/20 0.33
ICMT O60725 1/20 0.33
CA2 P00918 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7028880 0.96 SMN1; SMN2 (0.39) LMNASMN1; SMN2POLBGRK2MEN1
SCHEMBL7073956 0.94 KMT2A (0.38) LMNASMN1; SMN2POLBMEN1KMT2A
SCHEMBL7029993 0.94 LMNA (0.37) LMNASMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL7029121 0.94 KMT2A (0.38) LMNASMN1; SMN2POLBMEN1KMT2A
SCHEMBL7025592 0.93 LMNA (0.38) LMNASMN1; SMN2POLBGRK2MEN1
SCHEMBL7024985 0.89 SMN1; SMN2 (0.39) LMNASMN1; SMN2POLBGRK2MEN1
SCHEMBL7069790 0.88 LMNA (0.39) LMNASMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL7025725 0.88 KMT2A (0.41) LMNASMN1; SMN2POLBMEN1KMT2A
SCHEMBL7025743 0.87 KMT2A (0.39) LMNASMN1; SMN2POLBMEN1KMT2A
SCHEMBL7030800 0.87 LMNA (0.37) LMNASMN1; SMN2MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229228-A1 Novel alpha-sulfin-and alpha-sulfonamino acid amides SYNGENTA CROP PROTECTION, INC. 2003-12-11 US disclosed
EP-1274678-A1 NOVEL ALPHA-SULFIN- AND ALPHA-SULFONAMIDO ACID AMIDES Syngenta Participations AG (CH) 2003-01-15 EP disclosed
WO-2001079159-A1 NOVEL α-SULFIN- AND α-SULFONAMINO ACID AMIDES SYNGENTA PARTICIPATIONS AG (CH) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229228-A1 Novel alpha-sulfin-and alpha-sulfonamino acid amides ARSA, STS, CBR1 LMNA 4568/4885SMN1; SMN2 1574/4885POLB 4170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.